List of Participants. Members 1. Antonino Carbone. Lawrence Banks. Hubert E. Blum (unable to attend) Ethel Cesarman

Similar documents
List of Participants. Members 1. Helmut Bartsch. Michael Alavanja. Rajani A. Bhisey. Naomi Allen

Visiting scientists Dr Robert Baan Dr Aaron Cohen (until June 2012) Dr Christopher Portier

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Christophe Mérieux Conference: New Trends in Tumor Virology

IARC Handbook Volume 17: Colorectal Cancer Screening. Béatrice Lauby-Secretan, PhD on behalf of the IARC Working Group for Volume 17

LYON. FRANCE NOVEMBER / 2013 TRANSLATIONAL RESEARCH IN CHRONIC VIRAL HEPATITIS - BRIDGING BASIC SCIENCE AND CLINICAL RESEARCH

REPORT ON THE RESEARCH UNIT: Virology Department

WHO Workshop on Lassa Vaccine evaluation 24 April INSERM, 101 rue de Tolbiac, Paris LIST OF PARTICIPANTS

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

Molecular Basis for Therapy of AIDS-Defining Cancers

DNA Tumour Viruses. Virology, Pathogenesis and Vaccines. caister.com/dnatv2. Sally Roberts. Edited by:

Visiting scientists Dr Bruce Armstrong. (until November 2014)

A pilot study to determine the prevalence of HIV in individuals presenting for care with selected conditions:

ICGC launches new project and releases more genomic data on cancer

BioPlex 2200 Infectious Disease Panels

ESMO Symposium on Immuno-Oncology Programme book

Viral Hepatitis Prevention Board

THE PERFORMANCE OF CEPHEID XPERT HPV

United Kingdom National External Quality Assessment Service for Microbiology [Established 1971]

Global burden of cancers attributable to infections in 2008: a review and synthetic analysis

Recommended composition of influenza virus vaccines for use in the 2007 influenza season

Students Ms Cristina Artaza Irigaray (until November 2017) Mr Rosario Brancaccio Ms Lise Brault (until February 2017) Ms Maria Grazia Ceraolo

The number of new cases is expected to rise by about 70% over the next 2 decades.

Welcome to. The Fundamentals of International Clinical Research Workshop. Stevenson, Washington

Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva

VIRUS VACCINES & CANCER a story with two chapters

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

Recommended composition of influenza virus vaccines for use in the influenza season

Assessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study

Infectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance

A Summary of Childhood Cancer Statistics in Australia,

Staying on top of the current research landscape with InCites Benchmarking & Analytics: An immuno-oncology case study

Undetectable = Untransmittable. Mariah Wilberg Communications Specialist

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Gastric Cancer Care: From evidence to practice

Access to treatment and disease burden

IARC A UNIQUE AGENCY. Cancer research for cancer prevention

INCREASED SCREENING CUT-OFF LEVELS AND IMPACT OF A PLASMA PROTEIN ALGORITHM..??

VIRUSES AND BREAST CANCER

This meeting has been made possible by an independent grant from Roche.

Global EHS Resource Center

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

Low and Lower Fertility

3.1 PHASE 2 OF THE GLOBAL PROJECT

Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks

Virology. Brochure. 4 th World Congress on. San Antonio, USA October 06-08, 2014

Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues. September OTA-BP-H-163 GPO stock #


Research Priorities to Inform Public Health and Medical Practice for Domestic Zika Virus: A Workshop

Working Group on H5N1 Influenza Vaccines

Annie J. Sasco, MD, MPH, MS, DrPH

Professor Caroline Sabin

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

Industry Relationships and Institutional Affiliations

Allied Health: Sustainable Integrated Health Care for all Australians

Q and A - the PARTNER Study: new results from PARTNER 2

Promoting Cervical Screening Information for Health Professionals. Cervical Cancer

Cancer in transition: the human development index and the global disease burden 2008 and Freddie Bray

CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS

Silvia Franceschi Infections and Cancer Epidemiology Group International Agency for Research on Cancer Lyon, France

CONTENTS NOTE TO THE READER... 1

Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

HPV, Cancer and the Vaccination Programme

OVARIAN. CANCER Optimal Therapy. Update ADVANCED. 12 th International Symposium. Valencia, 22 nd February

Ms Brigitte Kajo Ms Michelle Mainaud (until June 2010) Ms Annick Papin Ms Dorothy Russell. Website:

Main developments in past 24 hours

SUMMARY OF THE DISCUSSION AND RECOMMENDATIONS OF THE SARS LABORATORY WORKSHOP, 22 OCTOBER 2003

Current State of Global HIV Care Continua. Reuben Granich 1, Somya Gupta 1, Irene Hall 2, John Aberle-Grasse 2, Shannon Hader 2, Jonathan Mermin 2

«Previous Next» IACC/OARC Autism Spectrum Disorder Publications Analysis: The Global Landscape of Autism Research, July New!

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report of the Advisory Group

Course in Cancer Metabolism

Terms and Conditions. VISA Global Customer Assistance Services

Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations

Population- based cancer survival estimates

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia

J. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9

ADDRESSING INEQUITIES IN CANCER PREVENTION CALLING FOR HPV VACCINATION FOR BOYS AND GIRLS

Influenza Update N 176

Professor J. Peter A. Lodge MD FRCS FEBS

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL SURGERY INITIATIVES 2015

Edited by Annamária Kis with the cooperation of Dr. Gábor Papp, Prof. Ekkehart Tillmanns, Dr. Tamás G. Weiszburg

SUPPLEMENTARY DATA. Telediab Study Group :

Deceased donation data in the UK. Paul Murphy National Clinical Lead for Organ Donation United Kingdom

Curriculum Vitae. Chun-Yu Lin, M.S.

Donate. Cellular Phone Towers

Childhood Vaccination and Immunisation

Feinberg Post-Program Evaluation on Global Health

Frontiers of Knowledge Award in Development Cooperation

Are 20 human papillomavirus types causing cervical cancer?

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

24 October 2017 Paris, France

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006

"Development and Clinical Progress. of DNA Vaccines" Program

Emerging infectious disease: trends in the literature on SARS and H7N9 influenza

Hepatitis C Virus Disease

Transcription:

List of Participants Members 1 Lawrence Banks Tumour Virology Laboratory International Centre for Genetic Engineering and Biotechnology Trieste 34012 Italy Antonino Carbone Department of Pathology IRCCS Foundation National Tumour Institute 20133 Milan Italy Hubert E. Blum (unable to attend) Department of Internal Medicine II University of Freiburg 79106 Freiburg Germany Ethel Cesarman Department of Pathology and Laboratory Medicine Weill Cornell Medical College New York, NY 10065 1 Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited specialists are marked by an asterisk. Each participant was asked to disclose pertinent research, employment, and financial interests. Current financial interests and research and employment interests during the past 3 years or anticipated in the future are identified here. Minor pertinent interests are not listed and include stock valued at no more than US$10 000 overall, grants that provide no more than 5% of the research budget of the expert s organization and that do not support the expert s research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All grants that support the expert s research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are listed as significant pertinent interests. 3

IARC MONOGRAPHS 100B Chien-Jen Chen 2 Genomics Research Center Academia Sinica Nankang, Taipei 11529 Taiwan, China Silvia de Sanjosé 3 Unit of Infections and Cancer Cancer Epidemiology Research Programme Catalan Institute of Oncology 08907 L Hospitalet de Ll., Barcelona Spain Dirk Dittmer Dept of Microbiology and Immunology Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, NC 27599-7290 Ingemar Ernberg Department of Microbiology, Tumor and Cell Biology Karolinska Institute 171 77 Stockholm Sweden Yue-yi Fang Institute of Parasitic Diseases Control of Guangdong Province Center for Disease Control and Prevention of Guangdong Province Guangzhou 510300 People s Republic of China Elizabeth T.H. Fontham School of Public Health Lousiana State University Health Sciences Center New Orleans LA 70112 David Forman Centre for Epidemiology and Biostatistics University of Leeds St James s Institute of Oncology St James s University Hospital Leeds LS9 7TF United Kingdom 2 Dr Chen s research unit receives support from Bristol-Myers-Squibb (which is developing treatments for hepatitis C and HIV-related conditions). 3 Dr de Sanjosé receives research support (not exceeding 10% of her unit s budget) from Merck (which makes HPV and hepatitis B vaccines) and Sanofi-Aventis (which makes a hepatitis B vaccine and treatments for HIV-related conditions). She also receives travel support for professional meetings (not exceeding 5 days/year) from Merck, GlaxoSmithKline (which makes HPV and hepatitis B vaccines and treatments for HIV-related conditions), and Qiagen (which markets tests for HPV). 4

Participants Andrew Grulich 4 National Centre in HIV Epidemiology and Clinical Research University of New South Wales, Darlinghurst, New South Wales 2010 Australia Andrew J. Hall Dept of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London WC1E 7HT United Kingdom Rolando Herrero INCIENSA Foundation (Costa Rican Institute for Research & Training in Nutrition & Health) Torre La Sabana San José Costa Rica Sung-Tae Hong Department of Parasitology and Tropical Medicine College of Medicine Seoul National University Seoul 110-799 Korea Michael C. Kew Department of Medicine Groote Schuur Hospital and University of Cape Town and Department of Medicine University of Witwatersrand Johannesburg South Africa Paul F. Lambert McArdle Laboratory for Cancer Research University of Wisconsin School of Medicine and Public Health Madison, WI 53706 Renaud Mahieux 5 Retroviral Oncogenesis Team ENS Lyon U758 INSERM 69007 Lyon France Masao Matsuoka Laboratory of Virus Control Center for AIDS Research Institute for Virus Research Kyoto University Kyoto 606-8507 Japan 4 Dr Grulich serves as an advisor to Commonwealth Serum Laboratories (which markets an HPV vaccine) and his unit receives research support and travel support from them. Before 2008 Dr Grulich received travel and research support (less than 5% of his unit s budget) from GlaxoSmithKline (which makes HPV and hepatitis B vaccines and treatments for HIV-related conditions), travel support for one meeting from Gilead Science (which markets treatments for hepatitis B and HIV-related conditions) and Janssen-Cilag (which markets treatments for HIV-related conditions and is developing a treatment for hepatitis C), and in-kind research support (not exceeding 1% of his unit s research budget) from Becton-Dickinson (which markets tests for Helicobacter pylori). None of this work is related to matters before a court or government agency. 5 Dr Mahieux served briefly as a consultant to MP Biomedicals (which makes tests for Epstein-Barr virus and Helicobacter pylori), ending in 2007. 5

IARC MONOGRAPHS 100B Francis Mégraud Laboratory of Bacteriology CHU Pellegrin INSERM U853 33076 Bordeaux France Steven Moss 6 GI & Liver Research Center Rhode Island Hospital/Brown University Providence, RI 02903 Nancy Mueller (emerita) Department of Epidemiology Harvard School of Public Health Brookline, MA 02445 Nubia Muñoz 7 (retired) 69005 Lyon France Edward L. Murphy Departments of Laboratory Medicine & Epidemiology/Biostatistics University of California, San Francisco and Blood Systems Research Institute San Francisco, CA 94118 Robert Newton Epidemiology and Genetics Unit Department of Health Sciences University of York Heslington, York, YO10 5DD United Kingdom Katja Polman Dept of Parasitology Prince Leopold Institute of Tropical Medicine 2000 Antwerp Belgium Mark Schiffman Hormonal & Reproductive Epidemiology Branch Division of Cancer Epidemiology & Genetics National Cancer Institute National Institutes of Health Rockville, MD 20892 6 Dr Moss served as a consultant (not exceeding 1% of total professional compensation) to Nycomed (which markets treatments for gastric disease associated with Helicobacter pylori through its Altana subsidiary) until 2008. This work was not related to matters before a court or government agency. He also serves on a speakers bureau (not exceeding 2% of time or compensation) for Otsuka (which markets tests for H. pylori through its Meretek subsidiary). 7 Dr Muñoz is retired from the International Agency for Research on Cancer and serves as a consultant to Sanofi-Pasteur (which makes hepatitis B vaccines and treatments for HIV-related conditions) and Merck (which markets HPV and hepatitis B vaccines). She also receives honoraria and travel support from these companies for lectures on HPV and HPV vaccines. 6

Participants Thomas Schulz Department of Virology Hannover Medical School Hannover 30625 Germany Diego Serraino Department of Epidemiology and Biostatistics Reference Centre in Oncology 33081 Aviano, PN Italy Freddy Sitas Cancer Research Division Cancer Council New South Wales Kings Cross, NSW 1340 Australia Banchob Sripa Tropical Disease Research Laboratory Division of Experimental Pathology Faculty of Medicine Khon Kaen University Khon Kaen 40002 Thailand Birgitte Jyding Vennervald DBL Center for Health Research and Development Faculty of Life Sciences University of Copenhagen 1871 Frederiksberg C Denmark Denise Whitby Viral Oncology Section AIDS and Cancer Virus Program SAIC-Frederick National Cancer Institute Frederick, MD 21702 Fabien Zoulim INSERM Unit 871 Molecular Pathobiology and New Treatments of Viral Hepatitis 69003 Lyon, France Harald zur Hausen (unable to attend) German Cancer Research Centre 69120 Heidelberg Germany Sherri Oliver Stuver Department of Epidemiology Boston University School of Public Health Boston, MA 02118 7

IARC MONOGRAPHS 100B Representatives Donald G. Blair Cancer Etiology Branch Division of Cancer Biology National Cancer Institute Rockville, MD 20892 Observers Franco M. Buonaguro Department of Experimental Oncology National Cancer Institute Fond. G. Pascale 80131 Naples Italy Alison Fiander Department of Obstetrics & Gynaecology Wales College of Medicine Cardiff University Cardiff, CF14 4XN United Kingdom IARC Secretariat Rosita Maria Accardi-Gheit Robert Baan (Rapporteur, Viruses Mechanistic and Other Relevant Data) Lamia Benbrahim-Tallaa (Rapporteur, Cancer in Experimental Animals) Véronique Bouvard (Responsible Officer; Rapporteur, Viruses Mechanistic and Other Relevant Data) Karina Braga Ribeiro Rafael Carel (Visiting Scientist) She-Chun Chuang Gary Clifford Vincent Cogliano (Head of Programme) Fatiha El Ghissassi (Rapporteur, Worms and Helicobacter pylori Mechanistic and Other Relevant Data) Silvia Franceschi Crystal Freeman (Rapporteur, Viruses Cancer in Humans) Laurent Galichet (Editor) Tarik Gheit Yann Grosse (Rapporteur, Cancer in Experimental Animals) Neela Guha (Rapporteur, Viruses Cancer in Humans) Farhad Islami Béatrice Lauby-Secretan (Rapporteur, Worms and Helicobacter pylori Exposure Data, Cancer in Humans) Catherine De Martel Martyn Plummer Hai-Rim Shin Kurt Straif (Rapporteur, Viruses Cancer in Humans) Massimo Tommasino Thérèse Truong Salvatore Vaccarella Hugo de Vuyst Nualnong Wongtongkam 8

Participants Post-meeting Scientific Assistance Han Kang (Visiting Scientist) Washington, DC Administrative Assistance Sandrine Egraz Michel Javin Brigitte Kajo Helene Lorenzen-Augros Karine Racinoux Production Team Arthur Bouvard (Reproduction of Graphics) Elisabeth Elbers Anne-Sophie Hameau Sylvia Moutinho Dorothy Russell 9